PMID- 35021971
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220816
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 23
IP  - 7
DP  - 2022
TI  - Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications.
PG  - 692-710
LID - 10.2174/1389450123666220111115528 [doi]
AB  - The mechanistic target of rapamycin (mTOR) is a pivotal regulator of cell 
      metabolism and growth. In the form of two different multi-protein complexes, 
      mTORC1 and mTORC2, mTOR integrates cellular energy, nutrient and hormonal signals 
      to regulate cellular metabolic homeostasis. In type 2 diabetes mellitus (T2DM), 
      pathological conditions and end-organ complications can be attributed to aberrant 
      mTOR. Substantial evidence suggests that two mTOR-mediated signaling schemes, 
      mTORC1-p70S6 kinase 1 (S6K1) and mTORC2-protein kinase B (AKT), play a critical 
      role in insulin sensitivity and that their dysfunction contributes to the 
      development of T2DM. This review summarizes our current understanding of the role 
      of mTOR signaling in T2DM and its associated complications, as well as the 
      potential use of mTOR inhibitors in the treatment of T2DM.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Yang, Lin
AU  - Yang L
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, 
      China.
FAU - Zhang, Zhixin
AU  - Zhang Z
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, 
      China.
FAU - Wang, Doudou
AU  - Wang D
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, 
      China.
FAU - Jiang, Yu
AU  - Jiang Y
AD  - Department of Pharmacology and Chemical Biology, University of Pittsburgh School 
      of Medicine, Pittsburgh PA15261, USA.
FAU - Liu, Ying
AU  - Liu Y
AD  - School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Diabetes Complications
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/metabolism
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1/metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/metabolism
MH  - Signal Transduction
MH  - *TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - diabetic complications
OT  - mTOR inhibitor
OT  - mTORC1
OT  - mTORC2
OT  - pivotal regulator
OT  - type 2 diabetes mellitus
EDAT- 2022/01/14 06:00
MHDA- 2022/07/20 06:00
CRDT- 2022/01/13 05:37
PHST- 2021/08/03 00:00 [received]
PHST- 2021/10/21 00:00 [revised]
PHST- 2021/12/01 00:00 [accepted]
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/01/13 05:37 [entrez]
AID - CDT-EPUB-120089 [pii]
AID - 10.2174/1389450123666220111115528 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2022;23(7):692-710. doi: 10.2174/1389450123666220111115528.